Crohn’s Disease Pipeline report embraces in-depth commercial assessment and clinical assessment of the Crohn’s Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Crohn’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight
The dynamics of Crohn’s Disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2030. Companies across the globe are working toward the development of new treatment therapies for Crohn’s disease rigorously. Some of the key players in the Crohn’s Disease market includes:
UCB
Abbvie
Genetech
Gilead Sciences
Celgene Corporation
Millennium Pharmaceuticals
And many others
Drugs Covered
Filgotinib
Risankizumab
Etrolizumab
PDA-001
And many others
Crohn’s Disease Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Crohn’s Disease treatment.
-
Crohn’s Disease key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Crohn’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Scope of the report
-
The Crohn’s Disease Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Crohn’s Disease across the complete product development cycle, including all clinical and nonclinical stages.
-
It comprises of detailed profiles of Crohn’s Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
-
Detailed Crohn’s Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
-
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Crohn’s Disease.
Report Highlights
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Crohn’s Disease.
In the coming years, the Crohn’s Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Crohn’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Crohn’s Disease treatment market. Several potential therapies for Crohn’s Disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Crohn’s Disease market size in the coming years.
Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Crohn’s Disease) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Crohn’s Disease
3. Crohn’s Disease Current Treatment Patterns
4. Crohn’s Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Crohn’s Disease Late Stage Products (Phase-III)
7. Crohn’s Disease Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Crohn’s Disease Discontinued Products
13. Crohn’s Disease Product Profiles
14. Crohn’s Disease Key Companies
15. Crohn’s Disease Key Products
16. Dormant and Discontinued Products
17. Crohn’s Disease Unmet Needs
18. Crohn’s Disease Future Perspectives
19. Crohn’s Disease Analyst Review
20. Appendix
21. Report Methodology
Related Reports
Crohn’s Disease (CD) Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’s “Crohn’s Disease (CD) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Crohn’s Disease (CD), historical and forecasted epidemiology as well as the Crohn’s Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Crohn’s Disease (CD) Epidemiology Forecast to 2030
DelveInsight’s ‘Crohn’s Disease (CD) Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Crohn’s Disease (CD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/